Scholarlink

Background <p>The CD3xCD20 bispecific antibody epcoritamab demonstrated deep, durable responses with manageable safety in relapsed/refractory (R/R) follicular lymphoma (FL) in EPCORE NHL-3 (phase 1/2; NCT04542824). This analysis evaluated 3-year follow-up outcomes in Japanese patients.</p> Methods <p>Adults with CD20 + FL and ≥ 2 prior lines of therapy (LOTs) received subcutaneous epcoritamab (0.16/0.8-mg step-up doses; 48-mg full doses) until disease progression or death. The primary endpoint was overall response rate (ORR).</p> Results <p>Twenty-one patients received epcoritamab (median age: 65&#xa0;years; median prior LOTs:&#xa0;4; 57.1% double refractory; 57.1% progressed within 24&#xa0;months of any first-line treatment). At a median follow-up of 35&#xa0;months, the ORR was 95.2% and the complete response (CR) rate was 76.2%. Median duration of response, duration of&#xa0;CR, progression-free survival, and overall survival were not reached. At 3&#xa0;years, 66.7% and 93.3% of complete responders remained progression-free and alive, respectively. Minimal residual disease negativity was achieved in 88.9% (16/18) of evaluable patients. Common treatment-emergent adverse events included cytokine release syndrome (90.5%) and injection-site reaction (71.4%), all predominantly grade 1–2 and occurring in early treatment cycles, and none fatal.</p> Conclusions <p>Epcoritamab monotherapy provided durable long-term remission with favorable safety in Japanese patients with R/R FL over 3&#xa0;years of follow-up.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Three-year follow-up of epcoritamab therapy in Japanese patients with relapsed/refractory follicular lymphoma in EPCORE NHL-3

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月18日

查看全文
  • Koji Izutsu,
  • Daigo Akahane,
  • Tomomi Toubai,
  • Toko Saito,
  • Yuko Mishima,
  • Tomoaki Fujisaki,
  • Momoko Nishikori,
  • Takahiro Kumode,
  • Youko Suehiro,
  • Kenji Ishitsuka,
  • Poliana Patah,
  • Ami Takahashi,
  • Barbara D’Angelo Månsson,
  • Elena Favaro,
  • Noriko Fukuhara

摘要

Background

The CD3xCD20 bispecific antibody epcoritamab demonstrated deep, durable responses with manageable safety in relapsed/refractory (R/R) follicular lymphoma (FL) in EPCORE NHL-3 (phase 1/2; NCT04542824). This analysis evaluated 3-year follow-up outcomes in Japanese patients.

Methods

Adults with CD20 + FL and ≥ 2 prior lines of therapy (LOTs) received subcutaneous epcoritamab (0.16/0.8-mg step-up doses; 48-mg full doses) until disease progression or death. The primary endpoint was overall response rate (ORR).

Results

Twenty-one patients received epcoritamab (median age: 65 years; median prior LOTs: 4; 57.1% double refractory; 57.1% progressed within 24 months of any first-line treatment). At a median follow-up of 35 months, the ORR was 95.2% and the complete response (CR) rate was 76.2%. Median duration of response, duration of CR, progression-free survival, and overall survival were not reached. At 3 years, 66.7% and 93.3% of complete responders remained progression-free and alive, respectively. Minimal residual disease negativity was achieved in 88.9% (16/18) of evaluable patients. Common treatment-emergent adverse events included cytokine release syndrome (90.5%) and injection-site reaction (71.4%), all predominantly grade 1–2 and occurring in early treatment cycles, and none fatal.

Conclusions

Epcoritamab monotherapy provided durable long-term remission with favorable safety in Japanese patients with R/R FL over 3 years of follow-up.